[go: up one dir, main page]

NO20091945L - Myke kapsler omfattende palonosetronhydroklorid med forbedret stabilitet og biotilgjengelighet - Google Patents

Myke kapsler omfattende palonosetronhydroklorid med forbedret stabilitet og biotilgjengelighet

Info

Publication number
NO20091945L
NO20091945L NO20091945A NO20091945A NO20091945L NO 20091945 L NO20091945 L NO 20091945L NO 20091945 A NO20091945 A NO 20091945A NO 20091945 A NO20091945 A NO 20091945A NO 20091945 L NO20091945 L NO 20091945L
Authority
NO
Norway
Prior art keywords
bioavailability
improved stability
palonosetron hydrochloride
soft capsules
methods
Prior art date
Application number
NO20091945A
Other languages
English (en)
Other versions
NO342353B1 (no
Inventor
Daniele Bonadeo
Ricardo Braglia
Enrico Braglia
Giorgio Calderari
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091945(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of NO20091945L publication Critical patent/NO20091945L/no
Publication of NO342353B1 publication Critical patent/NO342353B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det tilveiebringes en fast, oral doseringsform av palonosetron hydroklorid, metoder for å anvende doseringformen for å behandle emesis, og metoder for å fremstille doseringsformene. Doseringsformene har forbedret stabilitet og biotilgjengelighet og foreligger fortrinnsvis i form av flytende, fylte kapsler.
NO20091945A 2006-10-24 2009-05-19 Myke kapsler omfattende palonosetron hydroklorid med forbedret stabilitet og biotilgjengelighet NO342353B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24
PCT/EP2007/009098 WO2008049552A1 (en) 2006-10-24 2007-10-19 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Publications (2)

Publication Number Publication Date
NO20091945L true NO20091945L (no) 2009-05-25
NO342353B1 NO342353B1 (no) 2018-05-07

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091945A NO342353B1 (no) 2006-10-24 2009-05-19 Myke kapsler omfattende palonosetron hydroklorid med forbedret stabilitet og biotilgjengelighet

Country Status (35)

Country Link
US (2) US20080152704A1 (no)
EP (1) EP1940366B9 (no)
JP (1) JP5144527B2 (no)
KR (1) KR101441459B1 (no)
CN (1) CN101573106B (no)
AR (1) AR063362A1 (no)
AT (1) ATE427742T1 (no)
AU (1) AU2007308378B2 (no)
BR (1) BRPI0718497B1 (no)
CA (1) CA2666512C (no)
CL (1) CL2007003055A1 (no)
CO (1) CO6160289A2 (no)
CR (1) CR10728A (no)
CY (1) CY1109914T1 (no)
DE (1) DE602007000856D1 (no)
DK (1) DK1940366T3 (no)
EA (1) EA016455B1 (no)
ES (1) ES2325339T3 (no)
GT (1) GT200900096A (no)
HN (1) HN2009000785A (no)
HR (1) HRP20090341T1 (no)
IL (1) IL198225A (no)
ME (1) ME01949B (no)
MX (1) MX2009004461A (no)
NO (1) NO342353B1 (no)
NZ (1) NZ576237A (no)
PL (1) PL1940366T3 (no)
PT (1) PT1940366E (no)
RS (1) RS50842B (no)
SI (1) SI1940366T1 (no)
SV (1) SV2009003238A (no)
TW (1) TWI367212B (no)
UA (1) UA97653C2 (no)
WO (1) WO2008049552A1 (no)
ZA (1) ZA200902773B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5433236B2 (ja) * 2006-01-27 2014-03-05 アプタリス ファーマテック，インコーポレイテッド 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
JP5787301B2 (ja) * 2006-01-27 2015-09-30 アデア ファーマシューティカルズ，インコーポレイテッド 弱塩基性薬および有機酸を含む薬物送達系
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
US20120253046A1 (en) * 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PH12012500887A1 (en) * 2009-11-18 2016-08-26 Helsinn Healthcare Sa Compositions for treating centrally mediated nausea and vomiting
CN106974912A (zh) 2011-10-18 2017-07-25 赫尔辛医疗股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
CN103446072A (zh) * 2012-06-02 2013-12-18 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
ES2692881T3 (es) * 2013-03-19 2018-12-05 Galenicum Health S.L. Composiciones farmacéuticas que comprenden un agente activo
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
KR20150073866A (ko) * 2013-12-23 2015-07-01 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) * 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4633608A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
KR20250125376A (ko) 2022-12-12 2025-08-21 알프레드 이. 티펜바흐어 게엠베하 운트 ＆ 코. 카게 네투피탄트 및 팔로노세트론을 포함하는 고정 용량 복합제

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
DE122005000027I2 (de) * 1989-11-28 2006-03-16 Roche Palo Alto Llc Tricyclische Verbindungen.
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
EP1940366A1 (en) 2008-07-09
CN101573106B (zh) 2013-07-24
NO342353B1 (no) 2018-05-07
EP1940366B1 (en) 2009-04-08
WO2008049552A1 (en) 2008-05-02
HN2009000785A (es) 2011-10-14
BRPI0718497B1 (pt) 2024-02-06
BRPI0718497A2 (pt) 2014-07-08
TW200827355A (en) 2008-07-01
EA016455B1 (ru) 2012-05-30
US20080152704A1 (en) 2008-06-26
CO6160289A2 (es) 2010-05-20
TWI367212B (en) 2012-07-01
CA2666512A1 (en) 2008-05-02
CR10728A (es) 2009-07-23
SI1940366T1 (sl) 2009-08-31
DK1940366T3 (da) 2009-06-29
NZ576237A (en) 2011-12-22
ME01949B (me) 2010-08-31
RS50842B (sr) 2010-08-31
ZA200902773B (en) 2010-03-31
SV2009003238A (es) 2009-11-09
PL1940366T3 (pl) 2009-09-30
CA2666512C (en) 2014-05-27
HRP20090341T1 (hr) 2009-07-31
US20170035748A1 (en) 2017-02-09
UA97653C2 (ru) 2012-03-12
HK1117769A1 (en) 2009-01-23
KR20090073234A (ko) 2009-07-02
PT1940366E (pt) 2009-06-17
CL2007003055A1 (es) 2008-03-24
AU2007308378B2 (en) 2013-02-21
EA200970396A1 (ru) 2009-10-30
ES2325339T3 (es) 2009-09-01
AR063362A1 (es) 2009-01-21
ATE427742T1 (de) 2009-04-15
GT200900096A (es) 2011-08-29
CN101573106A (zh) 2009-11-04
JP5144527B2 (ja) 2013-02-13
AU2007308378A1 (en) 2008-05-02
CY1109914T1 (el) 2014-09-10
IL198225A0 (en) 2009-12-24
MX2009004461A (es) 2009-09-16
IL198225A (en) 2013-03-24
JP2009507933A (ja) 2009-02-26
DE602007000856D1 (de) 2009-05-20
EP1940366B9 (en) 2009-12-02
KR101441459B1 (ko) 2014-09-18

Similar Documents

Publication Publication Date Title
NO20091945L (no) Myke kapsler omfattende palonosetronhydroklorid med forbedret stabilitet og biotilgjengelighet
NO2020027I1 (no) glasdegib, eventuelt i form av et farmasøytisk akseptabelt salt, inkludert maleatsaltet
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
MY149731A (en) Compounds
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
JO3754B1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
EA201001334A1 (ru) Твёрдый препарат гидрохлорида карипразина для перорального введения
EA201291421A1 (ru) Пероральные фармацевтические лекарственные формы, содержащие дабигатрана этексилат и его фармацевтически приемлемые соли
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
NO20073551L (no) Nikotinacetylkolinreseptorligander
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
NO20084826L (no) Ny administrasjonsform av racecadotril
WO2008156550A3 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
DK2350026T3 (da) Sulfoximinsubstituerede anilinopyrimidinderativer som cdk-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
MX2010001574A (es) Ligandos del receptor cannabinoide.
DK2448561T3 (da) Faste farmaceutiske fast dosis-sammensætninger omfattende irbesartan og amlodipin, deres fremstilling og deres terapeutiske anvendelse
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
GEP20135859B (en) Stable combined pharmaceutical composition
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
NO20091334L (no) Fremgangsmate for syntese av klopidogrel og nye former for farmasoytisk akseptable salter derav
EA200970816A1 (ru) Новая лекарственная форма
CY1118132T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ (1R,4R)-6'-ΦΘΟΡΟ-Ν,Ν-ΔΙΜΕΘΥΛ-4-ΦΑΙΝΥΛ-4',9'-ΔΙΥΔΡΟ-3´H-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ